Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly)

PFE 24.89

+1.0%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Judy who wrote (1046)	11/17/1998 7:00:00 PM
From: Anthony Wong	Read Replies (2) of 1722

Judy, the article in the previous post mentioned post mentioned Enbrel Message 6456653 Managed-care companies also are looking at whether to pay for new treatments for rheumatoid arthritis, a potentially crippling form of the disease. The U.S. Food and Drug Administration this month approved Enbrel, which was developed by Immunex Corp., a biotech company majority owned by American Home Products Corp. Bioengineered Drugs Bioengineered drugs are generally more expensive than traditional pharmaceuticals like the Cox-2s because they're tougher to develop and manufacture. The wholesale cost of Immunex's Enbrel, which last week won U.S. approval, is about $11,700 a year, versus about $3,500 for the more toxic generic drug methotrexate, now the standard of care for the disease, the company said. ''You've got to balance the cost difference with therapies that are much more targeted -- giving them fewer side effects -- and are able to deliver much more than traditional pharmaceuticals,'' said Peggy Phillips, Immunex senior vice president for pharmaceutical development. ''It's all about value.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next